Haemonetics wins approval of PerQseal Elite vascular closure system

Nasdaq rose 1.11% while Dow slipped 0.07%, with S&P 500 up 0.66%. VIX fell 1.55 points. Lockheed Martin delivered a C-130J-30 to the U.S. Navy. F.N.B. reported Q3 net income of $152.9M. Haemonetics got FDA approval for PerQseal Elite. Zions Bancorporation Q3 earnings rose 20% YoY. Crown Holdings Q3 EPS up to $2.08.

Haemonetics announced FDA approval for its PerQseal Elite device, which seals arterial openings in heart and vascular procedures. The company acquired the technology via its 2026 purchase of Vivasure Medical. Shares rose 1.2% in extended trading. Additional clinical data will be presented at an upcoming conference.

Haemonetics (HAE) received FDA approval for its PerQseal Elite vascular closure system, expanding its portfolio for large-bore procedures. The device showed 0% major complications in a study, with hemostasis in under a minute. The approval follows the acquisition of Vivasure Medical. HAE plans to present clinical data at an upcoming conference.

Haemonetics (HAE) received FDA approval for its PerQseal® Elite vascular closure system, expanding its large-bore closure device portfolio. The system, acquired via Vivasure Medical, offers sutureless closure for arterial procedures, with clinical data showing rapid hemostasis and no major complications. The company plans to present data at the TCT Conference.

Haemonetics (HAE) received FDA approval for the PerQseal Elite vascular closure system, expanding its U.S. portfolio after acquiring Vivasure in 2026. The approval is a step in the company's execution following the acquisition, according to AI Analyst.

Haemonetics' PerQseal Elite system, a sutureless vascular closure device, received FDA approval. The device stops bleeding in under a minute on average and is bioabsorbable. According to the company, it simplifies procedures like TAVR and improves patient comfort. Haemonetics plans to present clinical data at the TCT Conference in October.